

## BRINGING CLINICIANS TOGETHER TO DISCUSS CURRENT DRUG THERAPY

February 2018 • Vol. 15, No. 2

The following succinct analysis appeared in *Pharmacist's Letter*. Based on vol. 34. No. 2

---

### WOMEN'S HEALTH

New evidence will reignite controversy about breast cancer risk with hormonal contraceptives.

The lower estrogen doses and different progestins in newer hormonal contraceptives were generally thought to be safer than the older ones.

Now a study suggests that newer hormonal contraceptives also raise breast cancer risk by about 20%...similar to older options.

But tell women not to panic. Other evidence shows no risk.

And even with the new study, risk is very low. About 7,700 women need to use hormonal contraception for a year for one to be diagnosed with breast cancer. The risk remains very low even after 10 years of use... treating 5,300 women seems to lead to one more breast cancer diagnosis.

This analysis also suggests a possible breast cancer link with levonorgestrel IUDs (*Mirena*, etc)...but it's too soon to say if progestin or underlying risks are to blame. Explain the progestin-only pill, depot medroxyprogesterone, and implant aren't linked to breast cancer so far.

Continue to recommend, furnish, or prescribe a contraceptive based on patient preference, efficacy, safety, etc...and breast cancer risk.

No personal history of breast cancer. Feel comfortable recommending hormonal contraception. Point out benefits beyond preventing pregnancy... reducing ovarian and endometrial cancer risk, easing heavy periods, etc.

Reassure women with a family history of breast cancer or a BRCA gene mutation that most evidence suggests their breast cancer risk will not increase further with hormonal contraceptives.

But suggest NON-hormonal options instead as women age into their 50s...since breast cancer and clot risk increase with age.

Personal history of breast cancer. Avoid hormonal contraception.

Hear our team clarify the impact of the new evidence with *PL Voices*. Use our *How Safe Is My Birth Control?* handout to educate patients...and learn more in our CE, *Selecting & Prescribing Hormonal Contraception*.

(For more on this topic, see Clinical Resource #340203 at [PharmacistsLetter.com](http://PharmacistsLetter.com).)

Primary Reference – Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med* 2017;377:2228-39.

See LEADER NOTES for answers to discussion questions.

## DISCUSSION QUESTIONS

### OVERVIEW OF CURRENT THERAPY

1. What is known about hormonal contraceptives and the risk of breast cancer?

### ANALYSIS OF NEW STUDY

2. What type of study was this? How were the patients selected for inclusion?

3. How were the patient groups and outcomes defined?

4. What were the results of the prospective cohort study?

See [LEADER NOTES](#) for answers to discussion questions.

5. What were the strengths and weaknesses of the **prospective cohort study**?

6. Were the results expressed in terms we care about and can use?

#### HOW SHOULD THE NEW FINDINGS CHANGE CURRENT THERAPY?

7. Do the results change your practice? How?

#### APPLY THE NEW FINDINGS TO THE FOLLOWING CASE

G.E. is a 32 year old who presents to your office for her gynecologic exam. Her last pap smear was three years ago and has never been abnormal. Her only medication is a combined oral contraceptive (drospirenone 3 mg/ethinyl estradiol 20 mcg, *Yaz*, etc).

In updating her history, you note that she married four months ago and is not interested in having children. Also, her maternal aunt was diagnosed with breast cancer last year, and is now cancer free after undergoing bilateral mastectomy.

Since she does not want to become pregnant for the long-term, she would like to discuss alternative forms of contraception with you and the side effects profiles of each type.

See [LEADER NOTES](#) for answers to discussion questions.

**8. What are G.E.'s options for contraception and how do they compare?**

G.E. is interested in a one of the IUD options and asks about their effects on cancer risk, particularly breast cancer, in light of her aunt's recent diagnosis.

**9. How should you counsel G.E. regarding the risk of breast cancer with hormonal contraception?**

G.E. is most comfortable with avoiding hormonal contraception. You schedule insertion of the copper IUD during your next procedure clinic.

**10. What follow-up should be done after insertion of an IUD?**

See [LEADER NOTES](#) for answers to discussion questions.

## REFERENCES

Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes. *Ann Epidemiol* 2015;25:193-200.

Chuffa LG, Lupi-Junior LA, Costa AB, et al. The role of sex hormones and steroid receptors on female reproductive cancers. *Steroids*. 2017;118:93-108.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet*. 1996;347:1713-27.

Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep*. 2016;65:1-66.

Curtis KM, Peipert JF. Long-acting reversible contraception. *N Engl J Med*. 2017;376:461-8.

Evans G, Sutton EL. Oral Contraception. *Med Clin North Am*. 2015;99:479-503.

Lash TL, Fox MP, MacLehose RF, et al. Good practices for quantitative bias analysis. *Int J Epidemiol* 2014;43:1969-85.

Marchbanks PA, Curtis KM, Mandel MG, et al. Oral contraceptive formulation and risk of breast cancer. *Contraception* 2012;85:342-50.

Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med* 2017;377:2228-39.

**Additional Pharmacist's Letter Resources available at [PharmacistsLetter.com](http://PharmacistsLetter.com)**

Commentary, Applying Study Results to Patient Care: Relative Risk, Absolute Risk, and Number Needed to Treat. *Pharmacist's Letter/Prescriber's Letter*. October 2017.

Commentary, Glossary of Study Design and Statistical Terms. *Pharmacist's Letter/Prescriber's Letter*. October 2017.

Chart, Postmenopausal Hormone Therapy. *Pharmacist's Letter/Prescriber's Letter*. August 2017.

PL Voices, Choosing Hormone Therapy for Menopausal Symptoms. *Pharmacist's Letter/Prescriber's Letter*. August 2017.

Chart, Comparison of Oral Contraceptives and Non-Oral Alternatives. *Pharmacist's Letter/Prescriber's Letter*. June 2017.

PL Voices, Management of Menstrual Migraine. *Pharmacist's Letter/Prescriber's Letter*. June 2017.  
Commentary, Intrauterine Contraceptives: IUDs. *Pharmacist's Letter/Prescriber's Letter*. February 2017.

Chart, Contraception for Women With Chronic Medical Conditions. *Pharmacist's Letter/Prescriber's Letter*. August 2016.

Commentary, Hormonal Contraception in Older Women. *Pharmacist's Letter/Prescriber's Letter*. December 2015.

PL Voices, Choosing a Hormonal Contraceptive. *Pharmacist's Letter/Prescriber's Letter*. October 2015.

Chart, Choosing a Hormonal Contraceptive. *Pharmacist's Letter/Prescriber's Letter*. October 2015.

See LEADER NOTES for answers to discussion questions.

**PL Journal Club Contributing Editors:**

Lori Dickerson, PharmD, FCCP, *Editor*; Jennifer Nieman, PharmD, BCPS, *Assistant Editor*; Lisa D. Mims, MD, Department of Family Medicine, Medical Univ of South Carolina, Charleston, SC; Maribeth Porter, MD, Department of Community Health and Family Medicine, Univ of Florida, Gainesville, FL.

**Editors and Authors:** Jeff Jellin, PharmD, *Editor-in-Chief*; Sherri Boehringer, PharmD, *Senior Editor, VP Content*; Karen Davidson, PharmD, *Senior Editor Emeritus*; Tammie Armeni, RPh, PharmD, *Editor, Director of Continuing Education*; Melissa Blair, PharmD, FASHP, FCCP, BCPS; Sandye Chabot, PharmD; Lori Dickerson, PharmD, FCCP; Rachel Maynard, PharmD; Kimberly Palacios, PharmD, *Editors*; Stacy Hester, RPh, BCPS; Crystal Maric, BSc Pharm, MBA, ACPR, *Associate Editors*; Bethany Bryant, PharmD, BCPS; Vickie Danaher, PharmD; Leslie Gingo, PharmD, BCPS; Flora Harp, PharmD; Tanner Higginbotham, PharmD; Jeff Langford, PharmD, BCPS-AQ Cardiology; Jennifer Nieman, PharmD, BCPS; Toni Ripley, PharmD, FCCP, BCPS-AQ Cardiology, ASH-CHC; Brea Rowan, PharmD, BCPS; James Van, BSc Pharm; Don Weinberger, PharmD; Marlea Wellein, PharmD, BCPS, *Assistant Editors*; Karen Wilson, BA, *Manuscript Editor*; Minda Paglinawan, BA, *Assistant Manuscript Editor*; Jenni Mangrum, BS, CPhT, *Assistant Education and Accreditation Editor*; Mark Graber, MD, MSHCE, FACEP, *Associate Clinical Editor*. **Consultants:** Jill Allen, PharmD, BCPS; Melanie Cupp, PharmD, BCPS; John Greiss, BSc Pharm, JD, LL.M.; Katie Lacaria, BSc Pharm, ACPR; Heidi Liston, BSc Pharm, PharmD; Lu-Ann Murdoch, BSc Pharm; Annette Murray, BSc Pharm; Jennifer Pennington, RN, BSN. **Editorial Advisors:** Christophe Anslinger, PA-C; Thomas Barringer, MD, FAHA, FNLA; Christopher Barry, PA-C, MMSc; William Bednar, MD; Larissa Bossaer, PharmD, BCPS; Robert Browne, MD, FAAFP; Stephen Brunton, MD; Holley Bush, PharmD; Peter Carek, MD, MS; Gary Choy, PharmD; Matthew Cline, MD; John Connolly, MD, FACP, FCCP; Sandra Counts, PharmD; Hikmat Fikrat, PhD; Rex Force, PharmD, FCCP, BCPS; Lawrence Frank, MD, FACP; Peter Garbeff, MD; Mark Garofoli, PharmD, MBA, CGP; Denise Gontiz, FNP-C; Charles Green, RPh; John Hambright, PharmD; Roland Hart, MD; Kyle Herbold, MD; Patricia Hatton, MD; Sydney Hendry, MD; Raissa Hill, DO; Jerry Jones, MD; Sheela Kapre, MD, FACP, FCCP; Adam Kaye, PharmD, FASCP, FCPhA; William Kehoe, PharmD, MA, FCCP, BCPS; Joshua Lenchus, DO, RPh, FACP, SFHM; Stanley Leong, PharmD; Kevin Maeda, PharmD; Christine Marsh, RPh; Eric Matheson, MD, MS; Christina McLaughlin, CPhT, EMT; Kay Niegel, RPh; Mike Pastrick, RPh; Ernest Pieper, PharmD; Daren Primack, MD, FACC; Barbara Rankin, MD; Jenna Reel, PharmD, BCPS, CPP, CDE; George Rishwain, MD; Sandy Robertson, PharmD; Edward Rogan, PharmD, BCACP; Gerald Rubley, MSN, PharmD; Ruth Ruffe, PharmD; AnnieMarie Santos, MD; David Schneider, MD; Allen Shaughnessy, PharmD, MMedEd; Jonathan Szkotak, PharmD, BCACP; Joshua Tessier, DO; Bruce Uch, PharmD; John David Williamson, MD, FAAFP; Raymond Wong, MD; William Yee, PharmD, FASHP, FCSHP; Kent Yep, RPh.

**Advisory Board:** Evan Ballard, MD, Jonesville Family Medical Ctr; Melvin Baron, PharmD, MPA, Univ of Southern Calif; Jan Basile, MD, FACP, Medical Univ of South Carolina; Robert Bickerton, MD, FACP; Reid B. Blackwelder, MD, FAAFP, East Tennessee State Univ; Kevin Brown, MD, FACOG, Texas A&M; Andrea Darby-Stewart, MD, HonorHealth; Anthony A. Donato, Jr., MD, MHPE, Reading Health System; Jan Drutz, MD, Baylor College of Med; Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, Fitzgerald Health Ed Associates; Barry Gidal, PharmD, RPh, Univ of Wisc; Robert Gotfried, DO, FAAFP; Martin Grajower, MD, FACP, FACE, Albert Einstein College of Med; B. Joseph Guglielmo, PharmD, UC San Francisco; Stuart Haines, PharmD, BCPS, BCACP, BC-ADM, FCCP, FASHP, FAPhA, Univ of Miss; Jefferson Harman, Jr, MD, Col, USAF, MC, FS; B. Mark Hess, MD, FACP; John Holman, MD, MPH, FAAFP; Eric Jackson, PharmD, FCCP, BCPS, Univ of Conn; Peter Jacobsen, PhD, DDS, Univ of the Pacific; Paul Jensen, MD, PharmD, FAAFP; Alan David Kaye, MD, PhD, DABA, DABPM, DABIPP, Louisiana State Univ; Steve Kayser, PharmD, UC San Francisco; Brian Kessler, DO, FACOPF, Lincoln-Memorial Univ; Edgar Lerma, MD, FACP, FASN, FAHA, Univ of Illinois at Chicago; Evan L. Lipkis, MD; Mark McConnell, MD, Oscar G. Johnson VA Medical Ctr; Stephen L. McKernan, BSc Pharm, ND, DO, FAAFP, Sam Houston State Univ; Steven E. Nissen, MD, MACC, Cleveland Clinic; Brenden O'Hara, RPh, BCACP, Blue Cross/Blue Shield of NC; Douglas S. Paauw, MD, MACP, Univ of Washington; Dan Perri, BSc Pharm, MD, FRCPC, McMaster Univ; Charles Ponte, BS, PharmD, FAAD, FAPhA, FASHP, FCCP, FNAP, West Virginia Schools of Pharmacy & Medicine; Joseph E. Scherger, MD, MPH, Eisenhower Medical Ctr; Arthur Shinn, PharmD, FASCP, Managed Pharmacy Consultants; Kelly Anne Spratt, DO, FACC, Univ of Pennsylvania; Dan Steiber, RPh, Genesis Pharma Consultants; Tom Vickery, PharmD, OPTION Care; C. Wayne Weart, PharmD, FAPhA, FASHP, BCPS, Medical Univ of South Carolina; Craig D. Williams, PharmD, FNLA, BCPS, Oregon Health & Science Univ.

**DISCLOSURE:**

The editors of this activity and its publisher, Therapeutic Research Center, have no relevant financial interests related to the products or services covered by this activity. Therapeutic Research Center/*Pharmacist's Letter* does not receive any commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. *Pharmacist's Letter* focuses on delivering completely objective, unbiased drug information and advice for the benefit of subscribers.

*Unbiased Evidence and Recommendations for the Pharmacist  
on New Developments in Drug Therapy*  
3120 West March Lane, Stockton, CA 95219  
TEL (209) 472-2240 ~ FAX (209) 472-2249  
[PharmacistsLetter.com](http://PharmacistsLetter.com)

The contents are copyrighted. © 2018 Therapeutic Research Center. All Rights Reserved.

See LEADER NOTES for answers to discussion questions.